Tags

Type your tag names separated by a space and hit enter

In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model.
Cancer Chemother Pharmacol. 2005 Jul; 56(1):70-4.CC

Abstract

Previously we have shown that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), which is isolated from the buds of Cleistocalyx operculatus, significantly inhibits the growth of human liver cancer SMMC-7721 cells and is able to induce apoptosis of SMMC-7721 cells in vitro. Here we report the antitumor effects of DMC in vivo, using a solid human tumor xenograft mouse model using human liver cancer SMMC-7721 cells. The average tumor weights in the control group and in mice injected with 150 mg/kg DMC were 1.42+/-0.11 g and 0.59+/-0.12 g, respectively. Flow cytometric analysis of the tumor cell population demonstrated an aneuploid peak (representing 33.60+/-0.80% of the total in mice injected with 150 mg/kg DMC). To our knowledge, this is the first time that chalcone compounds have been applied to a human tumor xenograft model.

Authors+Show Affiliations

State Key Laboratory of Bioreactor Engineering, Institute of Biochemistry, East China University of Science and Technology, Shanghai 200237, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15806415

Citation

Ye, Chun-Lin, et al. "In Vivo Antitumor Activity By 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a Solid Human Carcinoma Xenograft Model." Cancer Chemotherapy and Pharmacology, vol. 56, no. 1, 2005, pp. 70-4.
Ye CL, Liu JW, Wei DZ, et al. In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model. Cancer Chemother Pharmacol. 2005;56(1):70-4.
Ye, C. L., Liu, J. W., Wei, D. Z., Lu, Y. H., & Qian, F. (2005). In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model. Cancer Chemotherapy and Pharmacology, 56(1), 70-4.
Ye CL, et al. In Vivo Antitumor Activity By 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a Solid Human Carcinoma Xenograft Model. Cancer Chemother Pharmacol. 2005;56(1):70-4. PubMed PMID: 15806415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vivo antitumor activity by 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in a solid human carcinoma xenograft model. AU - Ye,Chun-Lin, AU - Liu,Jian-Wen, AU - Wei,Dong-Zhi, AU - Lu,Yan-Hua, AU - Qian,Feng, Y1 - 2005/04/02/ PY - 2004/05/11/received PY - 2004/08/13/accepted PY - 2005/4/5/pubmed PY - 2005/7/6/medline PY - 2005/4/5/entrez SP - 70 EP - 4 JF - Cancer chemotherapy and pharmacology JO - Cancer Chemother Pharmacol VL - 56 IS - 1 N2 - Previously we have shown that 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone (DMC), which is isolated from the buds of Cleistocalyx operculatus, significantly inhibits the growth of human liver cancer SMMC-7721 cells and is able to induce apoptosis of SMMC-7721 cells in vitro. Here we report the antitumor effects of DMC in vivo, using a solid human tumor xenograft mouse model using human liver cancer SMMC-7721 cells. The average tumor weights in the control group and in mice injected with 150 mg/kg DMC were 1.42+/-0.11 g and 0.59+/-0.12 g, respectively. Flow cytometric analysis of the tumor cell population demonstrated an aneuploid peak (representing 33.60+/-0.80% of the total in mice injected with 150 mg/kg DMC). To our knowledge, this is the first time that chalcone compounds have been applied to a human tumor xenograft model. SN - 0344-5704 UR - https://www.unboundmedicine.com/medline/citation/15806415/In_vivo_antitumor_activity_by_2'4'_dihydroxy_6'_methoxy_3'5'_dimethylchalcone_in_a_solid_human_carcinoma_xenograft_model_ DB - PRIME DP - Unbound Medicine ER -